Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + mirtazapine + duloxetine + venlafaxine
- Development stage
- Unknown
- Lead developer
- Medical University of Vienna
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a sequential pharmacological treatment regimen used in a clinical trial conducted by the Medical University of Vienna for patients with major depressive disorder (MDD). The protocol involves initial treatment with the selective serotonin reuptake inhibitor (SSRI) escitalopram. In cases of non-response after six weeks, patients are switched to alternative antidepressants, including the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine, or the serotonin-norepinephrine reuptake inhibitors (SNRIs) duloxetine or venlafaxine. The trial utilizes hybrid PET/MR imaging with a [11C]DASB radiotracer and an acute citalopram challenge to identify biomarkers for predicting individual treatment response by monitoring serotonin transporter (5-HTT) occupancy and regional brain activation changes.
- Brand names
- Effexor
- Other names
- escitalopram + mirtazapine + duloxetine + venlafaxine-Medical University of Vienna-major depressive disorder
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)SERT (Sodium-dependent serotonin transporter)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on escitalopram + mirtazapine + duloxetine + venlafaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + mirtazapine + duloxetine + venlafaxine.